Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential

N(6)-methyladenosine (m(6)A) is the most prevalent and well-characterized internal chemical modification in eukaryotic RNA, influencing gene expression and phenotypic changes by controlling RNA fate. Insulin-like growth factor-2 mRNA-binding proteins (IGF2BPs) preferentially function as m(6)A effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Tian-Yu, Hong, Lian-Lian, Ling, Zhi-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245617/
https://www.ncbi.nlm.nih.gov/pubmed/37280679
http://dx.doi.org/10.1186/s40364-023-00499-0
Descripción
Sumario:N(6)-methyladenosine (m(6)A) is the most prevalent and well-characterized internal chemical modification in eukaryotic RNA, influencing gene expression and phenotypic changes by controlling RNA fate. Insulin-like growth factor-2 mRNA-binding proteins (IGF2BPs) preferentially function as m(6)A effector proteins, promoting stability and translation of m(6)A-modified RNAs. IGF2BPs, particularly IGF2BP1 and IGF2BP3, are widely recognized as oncofetal proteins predominantly expressed in cancer rather than normal tissues, playing a critical role in tumor initiation and progression. Consequently, IGF2BPs hold potential for clinical applications and serve as a good choice for targeted treatment strategies. In this review, we discuss the functions and mechanisms of IGF2BPs as m(6)A readers and explore the therapeutic potential of targeting IGF2BPs in human cancer.

Ejemplares similares